|
Pluri Inc
PLUR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Pluri Inc growth rates, revenue grew
by 193.69 % in I. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2385
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.31 %
Pluri Inc net loss decreased from $-7 millions, to $-6 millions in I. Quarter 2024,
• More on PLUR's Growth
|
|
Pluri Inc realized a net loss in trailing twelve months.
Pluri Inc realized cash reduction of $ -0.32 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 43.69.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.59.
• More on PLUR's Valuation
|
|
|
|
|
Pluri Inc realized net loss in trailing twelve months.
Pluri Inc realized cash outflow of $ -0.32per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 43.69.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.59.
• More on PLUR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com